1251 related articles for article (PubMed ID: 18669461)
1. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI
Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321
[TBL] [Abstract][Full Text] [Related]
4. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
Harmon CS; DePrimo SE; Figlin RA; Hudes GR; Hutson TE; Michaelson MD; Négrier S; Kim ST; Huang X; Williams JA; Eisen T; Motzer RJ
Cancer Chemother Pharmacol; 2014 Jan; 73(1):151-61. PubMed ID: 24220935
[TBL] [Abstract][Full Text] [Related]
5. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
Deprimo SE; Bello CL; Smeraglia J; Baum CM; Spinella D; Rini BI; Michaelson MD; Motzer RJ
J Transl Med; 2007 Jul; 5():32. PubMed ID: 17605814
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
Barrios CH; Hernandez-Barajas D; Brown MP; Lee SH; Fein L; Liu JH; Hariharan S; Martell BA; Yuan J; Bello A; Wang Z; Mundayat R; Rha SY
Cancer; 2012 Mar; 118(5):1252-9. PubMed ID: 21898376
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
Escudier B; Roigas J; Gillessen S; Harmenberg U; Srinivas S; Mulder SF; Fountzilas G; Peschel C; Flodgren P; Maneval EC; Chen I; Vogelzang NJ
J Clin Oncol; 2009 Sep; 27(25):4068-75. PubMed ID: 19652072
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
George S; Blay JY; Casali PG; Le Cesne A; Stephenson P; Deprimo SE; Harmon CS; Law CN; Morgan JA; Ray-Coquard I; Tassell V; Cohen DP; Demetri GD
Eur J Cancer; 2009 Jul; 45(11):1959-68. PubMed ID: 19282169
[TBL] [Abstract][Full Text] [Related]
9. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
10. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Golshayan AR; George S; Heng DY; Elson P; Wood LS; Mekhail TM; Garcia JA; Aydin H; Zhou M; Bukowski RM; Rini BI
J Clin Oncol; 2009 Jan; 27(2):235-41. PubMed ID: 19064974
[TBL] [Abstract][Full Text] [Related]
11. 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment.
Oosting SF; Brouwers AH; van Es SC; Nagengast WB; Oude Munnink TH; Lub-de Hooge MN; Hollema H; de Jong JR; de Jong IJ; de Haas S; Scherer SJ; Sluiter WJ; Dierckx RA; Bongaerts AH; Gietema JA; de Vries EG
J Nucl Med; 2015 Jan; 56(1):63-9. PubMed ID: 25476536
[TBL] [Abstract][Full Text] [Related]
12. EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.
Davis ID; Long A; Yip S; Espinoza D; Thompson JF; Kichenadasse G; Harrison M; Lowenthal RM; Pavlakis N; Azad A; Kannourakis G; Steer C; Goldstein D; Shapiro J; Harvie R; Jovanovic L; Hudson AL; Nelson CC; Stockler MR; Martin A
Ann Oncol; 2015 Jun; 26(6):1118-1123. PubMed ID: 25701452
[TBL] [Abstract][Full Text] [Related]
13. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.
Elfiky AA; Cho DC; McDermott DF; Rosenberg JE; Fortner B; Antràs L; Chen K; Sheng Duh M; Jayawant SS; Oh WK; Atkins MB; Choueiri TK
Urol Oncol; 2011; 29(6):756-63. PubMed ID: 20451414
[TBL] [Abstract][Full Text] [Related]
14. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract][Full Text] [Related]
15. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
[TBL] [Abstract][Full Text] [Related]
16. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
[TBL] [Abstract][Full Text] [Related]
19. Tolerability of first-line therapy for metastatic renal cell carcinoma.
Porta C; Szczylik C
Cancer Treat Rev; 2009 May; 35(3):297-307. PubMed ID: 19249157
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
